New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
09:23 EDTWWWW, GIGA, XGTI, VRTX, OHRP, MU, RDEN, GOOG, KNOP, SAIC, WAGOn The Fly: Pre-market Movers
HIGHER: Vertex (VRTX), up 48% after Phase 3 studies of Lumacaftor/Ivacaftor met primary endpoint... xG Technology (XGTI), up 65% after teaming up with Science Applications International (SAIC) to provide services to CERDEC... Micron (MU), up 1% after upgraded at Needham following better than anticipated Q3 earnings. LOWER: (WWWW), down 9.3% after downgraded at B. Riley following Google's (GOOG) entrance into domain registration... Elizabeth Arden (RDEN), down 7.6% after Chief Marketing Officer resigns, company announces restructuring... Walgreens (WAG), down 1% after reporting lower than expected Q3 earnings and saying it is experiencing increased pressure on pharmacy gross profit margins... Giga-tronics (GIGA), down 14.5% after Q4 results are lower than analyst's expectations... KNOT Offshore Partners (KNOP), down 7.4% after filing to sell 4.6M common units... Ohr Pharmaceuticals (OHRP), down 12.3% after the company said that there were no significant differences in the frequency of Lucentis PRN injections, which was the primary endpoint of its Squalamine eye drop Phase II study.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 >>
September 22, 2015
16:00 EDTMUOptions Update; September 22, 2015
Subscribe for More Information
09:33 EDTMUActive equity options trading on open
Subscribe for More Information
09:09 EDTGOOGFrontier says adds Nest cam, Nest Protect to product offerings
Subscribe for More Information
08:23 EDTVRTXAnalysts say buy select biotech stocks ahead of Clinton drug plan
Ahead of Presidential candidate Hillary Clinton laying out her plan to tackle "price gouging" in the specialty drug market at an event in Iowa later today, analysts at research firms Jefferies and Piper Jaffray are recommending select biotech stocks that they view as buys amid the weakness in the space. DEBATE: Biotech stocks broadly declined yesterday, with the NASDAQ Biotechnology index (IBB) sliding roughly 4.4%, after privately-held Turing Pharmaceuticals made headlines by enacting a 5,000% price increase on a 62-year-old drug that fights complication of AIDS and cancer. Furor around the sudden price hike for Turing's Daraprim reignited a debate around drug prices that previously embroiled costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni. The news also follows Presidential candidate Bernie Sanders issuing a letter in August to Valeant (VRX) and Pfizer's (PFE) Hospira, in which he requested information on the "enormous" price increases of two drugs Valeant acquired earlier in the year. Presidential candidate Hillary Clinton sent the debate to center stage yesterday by criticizing the "outrageous" prices of specialty drugs and promising to lay out a plan today to tackle "price gouging" in the specialty drug market. Clinton's proposal, which she'll outline in a speech in Iowa later today, would force pharmaceutical companies to reinvest their profits into research, allow for more generic and imported drugs and allow Medicare to negotiate lower drug costs and cap out-of-pocket expenses, according to details of the plan shared with USA Today. Zeke Emanuel, chair of medical ethics and health policy at the University of Pennsylvania, appeared on Nightly Business Report to discuss the problem of high drug prices and his suggested solutions. During his interview, Emanuel contended that giving Medicare the ability to negotiate drug prices may drive up prices for everyone else. DEFENSES: The Jefferies Biotechnology research team, led by Brian Abrahams, Eun Yang and Biren Amin, say their Washington D.C. consultants indicate the recent political rhetoric around drug pricing is unlikely to result in any substantive future policy changes that would impact biotech sector fundamentals. As such, they recommend using yesterday's selloff to buy select companies including Celgene (CELG), BioMarin (BMRN) and Alkermes (ALKS). Pricing concerns are nothing new, and will likely continue to be a headwind for the sector, the analysts tell investors in a research note. Hillary Clinton's proposal to combat drug pricing is likely to include "some combination of old and tried policies that have been out there for a few years," they write. The analysts also like shares of AMAG Pharmaceuticals (AMAG), Alder Biopharmaceuticals (ALDR) and Cempra (CEMP). Meanwhile, Piper Jaffray analyst Edward Tenthoff recommends buying shares of Vertex Pharmaceuticals (VRTX) following yesterday's selloff. Tenthoff believes that drugs like Vertex's Orkambi will maintain premium pricing because of the disease modifying value to patients and payors. Orkambi is approved to treat cystic fibrosis in patients 12 years and older. The analyst reiterates an Overweight rating on Vertex with a $163 price target. DOWNGRADE: Brean Capital analyst Difei Yang downgraded Horizon Pharma (HZNP) to Hold saying "unsettling recent developments" make the stock's premium valuation no longer justified. The public discussion on high drug prices is a negative for the company while its attempt to acquire Depomed (DEPO) is unlikely to result in a completed deal, Yang tells investors in a research note. Further, Horizon's prescription trends are showing weakness, said Yang, who views the stock as more risky than in the past. PRICE ACTION: Horizon closed yesterday down $2.93, or 9.2%, at $28.99, while Vertex dropped $5.97, or 4.8%, to $118.19. A number of the biggest stocks in biotechnology were also weak yesterday, with Gilead sliding about 2.5%, Amgen (AMGN) dropping 2.3%, Celgene declining 2.8% and Biogen (BIIB) falling more than 5.5%.
07:41 EDTMURaymond James to hold a conference
North American Equities Conference to be held in London, England on September 22.
07:15 EDTGOOGCloudFlare raises $110M from consortium of Google, Microsoft, others
Subscribe for More Information
06:40 EDTMUChip sector deal size up substantially in 2015, WSJ reports
Subscribe for More Information
05:58 EDTVRTXVertex pullback yesterday a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff recommends buying shares of Vertex Pharmaceuticals following yesterday's selloff. Biotech names pulled back after Presidential candidate Hillary Clinton announced her intention to reveal a drug pricing plan to prevent "gouging," Tenthoff tells investors in a research note. He believes, however, that drugs like Vertex's Orkambi will maintain premium pricing because of the disease modifying value to patients and payors. Orkambi is approved to treat cystic fibrosis in patients 12 years and older. The analyst reiterates an Overweight rating on Vertex with a $163 price target. The stock closed yesterday down $5.97 to $118.19.
05:54 EDTMUDRAM price declines likely to continue through 2015, says Piper Jaffray
Subscribe for More Information
September 21, 2015
16:39 EDTSAICSAIC awarded $210M supply chain management contract by DLA
Subscribe for More Information
13:08 EDTGOOGFrance's CNIL rejects Google's informal 'right to delisting' appeal
French data protection agency Commission Nationale de l'Informatique et des Libertes, or CNIL, rejected Google's appeal of a notice that would require it to apply user requests to remove websites from its search results across all of its domains. CNIL cited these reasons for the rejection: "Geographical extensions are only paths giving access to the processing operation. Once delisting is accepted by the search engine, it must be implemented on all extensions, in accordance with the judgment of the ECJ. If this right was limited to some extensions, it could be easily circumvented: in order to find the delisted result, it would be sufficient to search on another extension, namely to use another form of access to the processing. This would equate stripping away the efficiency of this right, and applying variable rights to individuals depending on the internet user who queries the search engine and not on the data subject. In any case, the right to delisting never leads to deletion of the information on the internet; it merely prevents some results to be displayed following a search made on the sole basis of a person's name. Thus, the information remains directly accessible on the source website or through a search using other terms. For instance, it is impossible to delist an event. In addition, this right is not absolute: it has to be reconciled with the public's right to information, in particular when the data subject is a public person, under the double supervision of the CNIL and of the court. Finally, contrary to what Google has stated, this decision does not show any willingness on the part of the CNIL to apply French law extraterritorially. It simply requests full observance of European legislation by non European players offering their services in Europe." Since the informal appeal has been rejected, the company must now comply with the formal notice. Otherwise, the President of the CNIL may designate a Rapporteur who may refer to the CNIL's sanctions committee with a view of obtaining a ruling on this matter. Reference Link
12:00 EDTGOOGGoogle, Shopify expand presence in BlackBerry's hometown, Reuters says
Subscribe for More Information
10:00 EDTMUOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aquinox (AQXP) initiated with an Outperform at Leerink... Callon Petroleum (CPE) initiated with a Sector Perform at RBC Capital... Constellium (CSTM) initiated with an Outperform at Cowen... Energy Focus (EFOI) initiated with an Outperform at Oppenheimer... Galectin Therapeutics (GALT) initiated with a Buy at H.C. Wainwright... Helix Energy (HLX) initiated with a Market Perform at Cowen... IPG Photonics (IPGP) initiated with a Buy at DA Davidson... Intrexon (XON) initiated with a Buy at Stifel... Micron (MU) initiated with an Overweight at Barclays... New Relic (NEWR) initiated with an Overweight at Pacific Crest... Rice Energy (RICE) initiated with a Buy at Jefferies... SanDisk (SNDK) initiated with an Equal Weight at Barclays... Simmons First National (SFNC) initiated with a Neutral at Piper Jaffray... South State (SSB) initiated with a Neutral at Piper Jaffray... TerraForm Global (GLBL) initiated with a Hold at Deutsche Bank... Trimble (TRMB) initiated with an Equal Weight at Morgan Stanley... inContact (SAAS) initiated with a Buy at Lake Street.
07:19 EDTGOOGGoogle Class A price target raised to $847 from $720 at JMP Securities
Subscribe for More Information
06:24 EDTGOOGEU's web rules won't discriminate against U.S. tech companies, WSJ reports
Subscribe for More Information
06:07 EDTMUServer DRAM prices are down 15% since beginning of Q3, DigiTimes says
DRAMeXchange said average contract prices for server DRAM chips are down 15% since the beginning of Q3 due to weak demand, reports DigiTimes. DRAMeXchange added that shipments of branded enterprise servers have decelerated and dropped due to a weak global economy and currency rate fluctuations. Reference Link
06:01 EDTGOOGGoogle holding event on September 29, The Verge reports
Google will hold its fall event on Tuesday, September 29, The Verge reports. According to the publication, Google is likely to introduce new Nexus smartphones -- one from LG and one from Huawei -- as well as an updated Chromecast. Reference Link
05:44 EDTMUSanDisk initiated with an Equal Weight at Barclays
Subscribe for More Information
05:41 EDTMUMicron initiated with an Overweight at Barclays
Barclays analyst Blayne Curtis started shares of Micron (MU) with an Overweight rating and $20 price target. Curtis believes near-term risk from weak DRAM demand is priced into the stock at current levels. He thinks 2016 will be improved demand and pricing. The analyst also initiated this morning shares of SanDisk (SNDK) with an Equal Weight rating.
September 20, 2015
21:07 EDTMUDialog to acquire Atmel in move towards Internet of Things
Atmel (ATML) reached an agreement Sunday to be acquired by Dialog Semiconductor in a deal valued at approximately $4.6B, or the equivalent of $10.42 per Atmel share. Jalal Bagherli, CEO of U.K.-based Dialog, remarked that the combined company will be "a diversified, high-growth market leader" in chips for mobile devices, connected vehicles, and the Internet of Things. In a subsequent Bloomberg interview regarding the deal, Bagherli explained, "We passed the computing era, we're at the height of the mobile era, and we're about to enter the IoT era." The news comes after several semiconductor mergers in 2015 amid slowing growth and saturated markets, with Intel (INTC) agreeing in June to acquire Altera (ALTR) and Avago (AVGO) striking a deal in May for Broadcom (BRCM). Note also China's apparent desire to control companies in the space, evidenced by state-owned firms China Electronics Corp. and Tsinghua's respective pursuits of Atmel and Micron (MU).
1 | 2 | 3 | 4 | 5 | 6 | 7 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use